2025
Glucarpidase for treatment of high-dose methotrexate toxicity
Gupta S, Kaunfer S, Chen K, Dias J, Vijayan A, Rajasekaran A, Prosek J, Truong H, Wood A, Bassil C, Renaghan A, Shah C, Zhang J, Glezerman I, Carlos C, Kelly K, Passero C, Drappatz J, Abudayyeh A, Shin D, Sperati C, Yelvington B, Kanduri S, Neyra J, Edmonston D, Shirali A, Bansal A, Geara A, Mithani Z, Ziolkowski S, Rashidi A, Jakubowski J, Pujari A, Bond D, Dotson E, Wall S, Patton J, Barreto J, Herrmann S, Sheikh M, Baz R, Lee J, Lucchesi N, Kolman M, Rasheed M, Afzal A, Kang D, Mahesh A, Hsu R, Nicolaysen A, Tefera K, Schretlen C, Miller R, Velez J, Flannery A, Aklilu A, Anand S, Chandrasekhara S, Donley V, Patel A, Ni J, Krishnamurthy S, Ali R, Yilmam O, Wells S, Ortega J, Green-Lingren O, Leaf R, Sise M, Nayak L, LaCasce A, Leung N, Leaf D. Glucarpidase for treatment of high-dose methotrexate toxicity. Blood 2025, 145: 1858-1869. PMID: 39760780, DOI: 10.1182/blood.2024026211.Peer-Reviewed Original ResearchAcute kidney injuryHigh-dose methotrexate toxicityKidney recoveryPatients treated with glucarpidaseRates of acute kidney injuryDay 7Time to deathHigh-dose methotrexateCox regression modelsGlucarpidase administrationDialysis-dependentMethotrexate toxicityMethotrexate initiationKidney injuryClinical dataGlucarpidaseCancer CenterNeutropeniaEnd pointsMethotrexatePatientsHospital dischargeOutcomesTarget trial emulation frameworkDays
2024
Exploring the Present and Imagining the Future Landscape of Onconephrology
Aklilu A, Shirali A. Exploring the Present and Imagining the Future Landscape of Onconephrology. Kidney360 2024, 5: 1377-1379. PMID: 39186390, PMCID: PMC11441807, DOI: 10.34067/kid.0000000000000544.Peer-Reviewed Original Research
2023
Chemotherapy-Associated Thrombotic Microangiopathy
Aklilu A, Shirali A. Chemotherapy-Associated Thrombotic Microangiopathy. Kidney360 2023, 4: 409-422. PMID: 36706238, PMCID: PMC10103319, DOI: 10.34067/kid.0000000000000061.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDrug-induced thrombotic microangiopathyThrombotic microangiopathyPlasma exchangePrimary atypical hemolytic uremic syndromeAtypical hemolytic uremic syndromeEnd-organ dysfunctionMicroangiopathic hemolytic anemiaSecondary thrombotic microangiopathyTherapeutic plasma exchangeTerminal complement inhibitorLarge multicenter studyHemolytic uremic syndromeRole of complementPotential treatment strategyProteinuria reductionSupportive careBlood pressureMulticenter studyTreatment courseUremic syndromeComplement inhibitionTreatment strategiesHemolytic anemiaAntiangiogenesis agentsComplement inhibitors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply